Tag: Health Care

Displaying 601 - 620 of 802 results.

Consent Order Will Preserve Competition in Markets for Certain General Anesthetics, Neuromuscular Blocking Agents, Antiemetics, and New Injectable Iron Replacement Therapies
The Federal Trade Commission today released the materials relating to the workshop on Health Care Competition Law and Policy, held on September 9-10, 2002. The workshop focused on the implications of competition law and policy for health care financing and delivery and considered the impact of...
Chairman Timothy J. Muris in a speech today announced that the Federal Trade Commission will hold hearings on health care and competition law and policy commencing in February 2003 and continuing throughout the year. The hearings will be hosted jointly by the FTC and the Antitrust Division of the...
Today, the Food and Drug Administration (FDA) proposed to clear away unnecessary roadblocks to the approval of generic drug products. I am encouraged by the FDA's important action to address the competitive problems existing in the approval process for generic drug products.
According to the staff of the Federal Trade Commission, a bill pending before the Ohio legislature that seeks to authorize competing physicians to engage in collective bargaining with health plans over fees and other contract terms likely would increase health care costs and reduce access to care...
Following a public comment period, the Commission has approved the issuance of final consent orders and responses to the commenters of record in the matters concerning Philips Electronics and Okie Corporation. The Commission vote to approve the final consent orders was 5-0. (FTC File Nos. 022-3095...
Following a public comment period, the Commission has approved the issuance of a modified final consent order in the matter concerning Biovail Corporation (Biovail) and its branded drug Tiazac. Through the modification to the proposed order, Biovail's time to divest the relevant assets has been...
  Following a public comment period, the Commission has approved a final consent order, without modifications, and a letter to the commenter of record in the matter concerning Immunex Corporation and Amgen Inc. The vote to approve the final order and response to the commenter was 5-0. (FTC File No...
Joe Simons, Director of the Federal Trade Commission's Bureau of Competition, today announced the formation of the Merger Litigation Task Force, which will be headed by Michael Cowie, an Assistant Director in the Bureau of Competition. The Task Force will be responsible for reinvigorating the...
System Health Providers and its parent corporation, Genesis Physicians Group, Inc., settled charges that they collectively bargained with health insurance firms to accept proposed fee schedules; discouraged members from entering into contracts directly with payers; and refused to...
Eight Denver, Colorado physician groups specializing in obstetrics and gynecology and their non-physician agent settled allegations that the practice group and other physicians entered into collective contracts in an effort to increase prices and terms of services when dealing with...
The Commission has approved the issuance of a final consent order in the matter concerning Biovail Corporation and Elan Corporation, plc, and authorized a response letter to be sent to the one commenter of record. The Commission vote to approve the final consent order and to issue the letter was 5...
Amgen settled antitrust charges that its proposed $16 billion acquisition of Immunex Corporation would reduce competition and tend to create a monopoly in the biopharmaceutical markets for neutrophil (white blood cell) regeneration factors; tumor necrosis factor (TNF) inhibitors; and...
Under the terms of a proposed consent agreement announced today, the Federal Trade Commission would allow Amgen Inc.'s (Amgen) proposed $16 billion acquisition of Immunex Corporation (Immunex) to proceed, provided the companies divest certain assets and license certain intellectual property rights...
In an initial decision filed on June 27, 2002 and announced today, Administrative Law Judge (ALJ) D. Michael Chappell dismissed all allegations of anticompetitive conduct in a March 2001 Federal Trade Commission complaint against pharmaceutical manufacturers Schering-Plough Corporation (Schering)...
Two Denver, Colorado-area physician organizations, Physician Integrated Services of Denver, Inc. (PISD), and Aurora Associated Primary Care Physicians, L.L.C. (AAPCP), along with their respective physician leaders and non-physician agent, have agreed to settle Federal Trade Commission charges that...

Pages